When Blood Sugar Control Comes at a Cost: What Men With Diabetes Need to Know About Their Medications and Erectile Health

For the roughly 37 million Americans living with diabetes, the pharmaceutical landscape has never looked more promising. A new generation of glucose-lowering agents—most notably GLP-1 receptor agonists like semaglutide and tirzepatide, and SGLT2 inhibitors like empagliflozin and dapagliflozin—has fundamentally changed how clinicians approach blood sugar management. These medications do not merely lower glucose; they reduce cardiovascular risk, promote weight loss, and in some cases appear to slow kidney disease progression.

Yet buried beneath the clinical enthusiasm is a conversation that rarely happens in the endocrinologist's office: what do these drugs do to a man's sexual health?

The answer, it turns out, is more complicated than a simple yes or no.

Diabetes and Erectile Dysfunction: The Baseline Problem

Before examining medication-specific effects, it is worth acknowledging the underlying challenge. Men with type 2 diabetes are approximately two to three times more likely to develop erectile dysfunction compared to men without the condition. The reasons are multifactorial: chronic hyperglycemia damages the small blood vessels and nerves that support penile erection, while the metabolic syndrome often accompanying diabetes—elevated blood pressure, obesity, dyslipidemia—further compromises vascular integrity.

In this context, any medication that meaningfully improves blood sugar control would theoretically be expected to help erectile function over time. And for many men, that is precisely what happens. The paradox, however, emerges when the mechanisms of certain drugs introduce new variables that can work against sexual health even as glycemic control improves.

GLP-1 Receptor Agonists: The Weight Loss Winners With a Complicated Profile

Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become cultural phenomena in the United States, celebrated for dramatic weight loss outcomes alongside their glucose-lowering effects. Weight reduction, in principle, should benefit erectile function—excess adipose tissue elevates estrogen levels, suppresses testosterone, and increases systemic inflammation, all of which impair sexual performance.

The reality, however, is more nuanced for some patients.

Testosterone suppression through rapid weight loss. When men lose weight rapidly—as often occurs on GLP-1 therapies—the hormonal environment can shift unexpectedly. Some researchers have noted transient reductions in testosterone during aggressive caloric restriction, a phenomenon thought to involve the hypothalamic-pituitary axis recalibrating in response to altered energy availability. For men already on the lower end of normal testosterone ranges, this temporary dip may be clinically meaningful.

Reduced libido as a direct drug effect. A subset of men on GLP-1 agonists report diminished sexual desire independent of other hormonal changes. While this side effect is not prominently listed in prescribing information, patient-reported outcomes from online forums and emerging observational data suggest it occurs with enough frequency to warrant clinical attention. The mechanism is not fully established, though central nervous system effects of GLP-1 receptors—which are expressed in the brain—may play a role.

Nausea and systemic fatigue. The gastrointestinal side effects of GLP-1 drugs are well-documented. Persistent nausea, fatigue, and reduced appetite can collectively diminish a man's general sense of well-being, creating a psychogenic component to sexual dysfunction even when no direct physiological mechanism is present.

SGLT2 Inhibitors: Genital Hygiene Concerns and Beyond

SGLT2 inhibitors work by causing the kidneys to excrete excess glucose through urine, effectively lowering blood sugar without requiring insulin. They are among the most cardioprotective agents in the diabetes pharmacopeia, and their benefits for men with heart failure or chronic kidney disease are well-established.

However, the mechanism that makes them effective—glycosuria, or glucose in the urine—creates a warm, sugar-rich environment that significantly increases the risk of genital mycotic infections. For men, this typically manifests as balanitis or balanoposthitis: inflammation of the glans penis and foreskin caused by fungal or bacterial overgrowth.

This is not a minor inconvenience. Recurrent genital infections cause pain, discomfort, and local inflammation that can directly interfere with sexual activity. They may also introduce psychological reluctance to engage in sexual contact, compounding any physiological effects on erectile function. Uncircumcised men appear to be at higher risk, though the condition can affect any male patient on these agents.

Beyond genital infections, some observational studies have identified associations between SGLT2 inhibitor use and changes in testosterone metabolism, though the evidence here remains preliminary and the clinical significance is debated among endocrinologists.

Metformin: The Old Standard and Its Quiet Testosterone Effect

For completeness, it is worth noting that metformin—still the most widely prescribed first-line diabetes medication in the United States—has long been associated with modest reductions in testosterone levels in some studies. The proposed mechanism involves metformin's effects on luteinizing hormone signaling and steroidogenesis. While the magnitude of this effect is generally considered small, men who are already borderline hypogonadal and who experience new or worsening erectile dysfunction after starting metformin may benefit from having their testosterone levels evaluated.

What to Discuss With Your Doctor Before Changing Regimens

None of the above should be interpreted as an argument against taking these medications. The cardiovascular and metabolic benefits of GLP-1 agonists and SGLT2 inhibitors are substantial, and for many men, the long-term improvement in blood sugar control will ultimately benefit sexual health more than it harms it. The goal is informed decision-making, not avoidance.

That said, the following questions are worth raising at your next appointment:

• Baseline sexual health assessment. Before starting a new diabetes medication, ask your physician to document your current erectile function. This creates a reference point for attributing any future changes.

• Testosterone monitoring. If you begin a GLP-1 agonist and notice reduced libido or worsening erectile function, request a total and free testosterone panel. This is a simple, inexpensive blood test that can clarify whether hormonal changes are contributing.

• Genital hygiene protocols on SGLT2 inhibitors. Your prescriber should counsel you on proper hygiene practices to reduce the risk of genital infections. Prompt treatment of any early symptoms is essential to prevent recurrence.

• Titration strategies. For GLP-1 drugs, slower dose escalation may reduce the severity of nausea and fatigue, potentially preserving quality of life—including sexual well-being—during the adjustment period.

• Concurrent ED treatment options. If erectile dysfunction is already present or develops after starting a new diabetes medication, discussing FDA-approved phosphodiesterase-5 inhibitors with your physician is entirely appropriate. These medications are generally safe for men with diabetes and can be used alongside most glucose-lowering agents, though a full medication review is always advisable.

The Bigger Picture: Managing Two Conditions, Not Just One

Men with diabetes face a compounded challenge: the disease itself predisposes them to erectile dysfunction, and the medications used to manage it may, in certain circumstances, introduce additional sexual health variables. This is not a reason for therapeutic nihilism—it is a reason for thoroughness.

The most effective approach is one in which a man's sexual health is treated as a legitimate clinical priority, not a secondary concern to be addressed only after every other metric is optimized. American men, culturally, have often been reluctant to raise sexual health concerns with their physicians. That reluctance, understandable as it may be, can result in years of treatable dysfunction going unaddressed.

If your diabetes management regimen has changed recently and you have noticed a shift in your sexual function, that observation deserves a conversation—not silence. The medications reshaping diabetes care in this country are genuinely remarkable. With the right information and the right clinical partnership, there is no reason they need to come at the cost of your sexual health.